CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 61 enrolled
Drug / intervention
Cabozantinibdrug
Likely dose
Cabozantinib 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01466036
NCT01466036Phase 2Completed
CompareCT.gov

An Open-Label, Phase II Study of Cabozantinib (XL184) in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Dana-Farber Cancer Institute·interventional·Posted Nov 7, 2011·Updated Mar 5, 2024

In Brief

A Phase 2 clinical trial evaluating Cabozantinib for Carcinoid Tumor and Pancreatic Neuroendocrine Tumor. Completed, enrolled 61 participants across 2 sites.

Detailed Summary

Cabozantinib works by blocking the growth of new blood vessels that feed a tumor. In addition to blocking the formation of new blood cells in tumors, cabozantinib also blocks pathways that may be responsible for allowing cancers cells to become resistant to other "anti-angiogenic" drugs. Cabozantinib has been studied or is being study in research studies as a possible treatment for various types of cancer, including prostate cancer, brain cancer, thyroid cancer, lung cancer, and kidney cancer. In this research study, the investigators wish to learn if cabozantinib is effective in treating patients with pancreatic neuroendocrine and carcinoid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoid Tumor, Pancreatic Neuroendocrine Tumor
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 7, 2011
Enrollment StartJul 1, 2012
Primary CompletionAug 1, 2021
Study CompletionDec 1, 2023
TodayJul 2, 2026
Enrollment to primary: 9.1 yearsPosted 14.7 years ago

Interventions

Cabozantinibdrug

60 mg QD orally in cycles of 28 days